Author

Tanya Gupta

Observed names: T* Gupta, T. Gupta

Observed institutions: University of California San Diego, Stanford Health Care, Stanford Medicine, Myriad Genetics, Stanford Cancer Institute, Stanford University

ORCID: 0000-0003-0698-9350

Observed ORCID: 0000-0003-0698-9350

OpenAlex ID: A5062530889

Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk

2017 · Jennifer L. Caswell-Jin, Tanya Gupta, et al. · Genetics in Medicine · 220

Online Communities as Sources of Peer Support for People Living With Cancer: A Commentary

2018 · Tanya Gupta, Lidia Schapira · Journal of Oncology Practice · 37

Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer

2022 · Tanya Gupta, Shaveta Vinayak, et al. · Breast Cancer Research and Treatment · 32

Considering the vascular hypothesis for the pathogenesis of small intestinal atresia: A case control study of genetic factors

2013 · Tanya Gupta, Wei Yang, et al. · American Journal of Medical Genetics Part A · 19

Neoadjuvant Therapy in Breast Cancer

2022 · Megan L. Troxell, Tanya Gupta · Surgical pathology clinics · 13

Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing?

2018 · Evan T. Hall, Divya Parikh, et al. · JCO Precision Oncology · 9

Incident comorbidities after tamoxifen or aromatase inhibitor therapy in a racially and ethnically diverse cohort of women with breast cancer

2022 · Tanya Gupta, Natasha Purington, et al. · Breast Cancer Research and Treatment · 6

Aromatase inhibitor-induced arthralgia ameliorated by Mediterranean diet and active lifestyle guided by continuous glucose monitoring: a case report and review of the literature

2024 · Kalin L. Wilson, Richard E. Grewelle, et al. · Frontiers in Oncology · 1

95MO Circulating tumor DNA (ctDNA) dynamics in patients (pts) receiving capecitabine (CAPE) for early-stage triple-negative breast cancer (eTNBC) with an incomplete response to neoadjuvant therapy (NAT)

2023 · T. Gupta, C. Garcia, et al. · ESMO Open · 1

Pathogenic germline mutations in emerging cancer genes: What happens after panel testing?

2017 · Evan Thomas Hall, Divya Ahuja Parikh, et al. · Journal of Clinical Oncology · 1

Abstract P1-12-05: Improving Outcomes in Patients With High-risk Breast Cancer: Outcomes and Analysis From an Educational Program on HR+/HER2- Early and Metastatic Breast Cancer

2025 · Jerfiz Constanzo, Yara Abdou, et al. · Clinical Cancer Research

Treatment patterns among HCPs and concordance with expert recommendations in HER2-negative early breast cancer: Analysis of an interactive online treatment decision support tool.

2024 · Kelly G Brandt, Marie N. Becker, et al. · Journal of Clinical Oncology

Pathological complete response (pCR) association with a novel homologous recombination deficiency HRD signature (HRDsig) in patients with triple-negative breast cancer (TNBC) receiving neoadjuvant therapy (Tx).

2024 · Tanya Gupta, Ryon P Graf, et al. · Journal of Clinical Oncology

Abstract PS9-24: Incident comorbidities in a diverse cohort of women treated for early-stage, hormone receptor-positive breast cancer

2021 · Tanya Gupta, Natasha Purington, et al. · Cancer Research

Abstract PD8-06: Multiple-gene panel testing for hereditary cancer risk reveals a racial/ethnic disparity in genetic information

2017 · JL* Caswell-Jin, T* Gupta, et al. · Cancer Research

Works count: 15

Citation count: 339

H-index: 6

I10-index: 5